title: Reply to the letter to the editor 'clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC' by Ou et al.
authors.affiliation: Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange. Electronic address: siou@uci.edu.
authors.forename: S-H I
authors.initials: SI
authors.lastname: Ou
authors.affiliation: Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA.
authors.forename: J
authors.initials: J
authors.lastname: Pasi
mesh_terms: D000077548:Anaplastic Lymphoma Kinase; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D000077547:Crizotinib; D006801:Humans; D011720:Pyrazoles / Q000008:administration & dosage*; D011725:Pyridines / Q000008:administration & dosage*; D020794:Receptor Protein-Tyrosine Kinases / Q000235:genetics*
chemical_list: D011720:Pyrazoles; D011725:Pyridines; D000077547:Crizotinib; C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; D020794:Receptor Protein-Tyrosine Kinases